Clinical Trials on ARDS, Human in Australia

Total 451 results

Aqualung Therapeutics Corp.

Completed

First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100

ARDS, Human

Australia
Mathias Maleczek
Medical University of Vienna; Philips Austria GmbH

Completed

Advisory Lead ARDS Respirator Management (ALARM)

ARDS, Human

Austria
Peninsula Health
Baxter Healthcare Corporation; Monash University

Recruiting

Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury

ARDS, Human

Australia
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

Influenza

Australia, Singapore
Seqirus

Completed

Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years

Influenza

Australia
Kepler University Hospital

Completed

Prediction of Conversion From Vv-ECMO to Va-ECMO in COVID-19 Patients (ECMOPred-vvva)

ARDS Due to Disease Caused by SARS Co-V-2

Austria
Kirby Institute

Not yet recruiting

The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

Hepatitis C

Australia
The Alfred
Merck Sharp & Dohme LLC

Completed

Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2) (HYPER2)

Human Papillomavirus Infection | Human Papillomavirus

Australia
Emergent BioSolutions

Completed

Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)

Human Influenza

Australia
Apeptico Forschung und Entwicklung GmbH

Recruiting

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

ARDS

Austria, Germany
The Alfred
Merck Sharp & Dohme LLC

Completed

Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men (HYPER)

Human Papillomavirus

Australia
Seqirus

Completed

Study of a Pandemic Influenza Vaccine in Elderly Participants

Influenza

Australia
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute; Flinders University

Completed

A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults (FLU003)

Influenza

Australia
AVIR Green Hills Biotechnology AG

Completed

Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers (GHBCS-01)

Seasonal Human Influenza

Austria
Cocrystal Pharma, Inc.
Cocrystal Pharma Australia Pty Ltd.; Linear Clinical Research

Completed

CC-42344 Safety Study in Healthy Participants

Influenza A

Australia
Seqirus

Completed

Phase II Study of Pandemic Influenza Vaccine

Influenza

Australia
VaxInnate Corporation

Unknown

Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years

Influenza

Australia
Wuhan BravoVax Co., Ltd.
Novotech (Australia) Pty Limited; Shanghai BravoBio Co., Ltd.

Not yet recruiting

Phase I Clinical Trial of a Candidate HPV Vaccine

Human Papillomavirus Infection

Australia
Seqirus

Completed

Study of a Pandemic Influenza Vaccine in Children

Influenza

Australia
Seqirus

Completed

Study of a Pandemic Influenza Vaccine

Influenza

Australia
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute

Completed

Recombinant H7 Hemagglutinin Influenza Vaccine Trial (FLU007)

Influenza, Avian

Australia
Novavax

Completed

A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1

Avian Influenza

Australia
The Alfred
Merck Sharp & Dohme LLC

Completed

Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination (Impress)

Human Papillomavirus

Australia
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

Respiratory Disorders

Australia
GlaxoSmithKline

Completed

Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™

Influenza

Australia, Brazil
Enyo Pharma
CPR Pharma Services Pty Ltd, Australia

Completed

Drug Drug Interaction Study for EYP001 With Entecavir

Hepatitis B, Chronic

Australia
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults

Influenza Caused by the Novel Influenza A (H1N1) Virus

Australia
Seqirus

Completed

A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults (CSL's IVV)

Influenza

New Zealand, Australia
Fremantle Hospital and Health Service

Completed

In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia

Hepatitis C

Australia
Abbott

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season

Influenza

Australia
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B (PIPET B)

Pandemic Influenza

Australia
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza (PIPET C)

Pandemic Influenza

Australia
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza (PIPET A)

Pandemic Influenza

Australia
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute Ltd

Not yet recruiting

Covid-19 and Influenza Oral Vaccine Study

Influenza, Human | covid19 Infection

Australia
Pantec Biosolutions AG
Medical University of Vienna

Completed

Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine

Influenza in Human

Austria
Codagenix, Inc

Active, not recruiting

Intramuscular CodaVax-H1N1 in Healthy Adults

Influenza, Human

Australia
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)

Influenza

Australia
Codagenix, Inc

Completed

Safety Study of Live Attenuated Influenza Vaccine, CodaVax

Influenza

Australia
Seqirus

Completed

A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population

Influenza

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Australia
Arcturus Therapeutics, Inc.
Novotech (Australia) Pty Limited; Seqirus

Recruiting

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Influenza, Human

Australia
Codagenix, Inc

Completed

Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray

Influenza

Australia
Respirio Pty Ltd

Completed

Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B

Influenza

Australia
Huahui Health

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

Hepatitis B

Australia
FixHepC

Unknown

Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods (REDEMPTION)

Hepatitis C

Australia
TetraLogic Pharmaceuticals

Terminated

Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B

Hepatitis B

Australia
Vir Biotechnology, Inc.

Completed

Study of VIR-2482 in Healthy Volunteers

Influenza A

Australia
Immune Targeting Systems Ltd
INCResearch Australia Pty Limited

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)

Influenza A

Australia
Kirby Institute

Recruiting

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)

Hepatitis C

Australia
Kirby Institute

Completed

Study of the Prevention of Anal Cancer (SPANC)

Cancer | Human Papillomavirus

Australia

3

Subscribe